SCHEMBL12043244

SCHEMBL12043244

Cc1ccc(N2CCN(CCC(=O)NC3CCN(c4ccc([N+](=O)[O-])c(C(F)(F)F)c4)CC3)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SIRT6 Q8N6T7 2/20 0.54
▸ DRD2 P14416 1/20 0.43
▸ DRD3 P35462 1/20 0.43
▸ SERPINE1 P05121 3/20 0.42
▸ LMNA P02545 2/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA7 P43166 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ MAPT P10636 5/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ HTT P42858 1/20 0.41
▸ TMEM97 Q5BJF2 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12043295 0.95 SIRT6 (0.52) SIRT6DRD2DRD3SERPINE1LMNA
SCHEMBL12059834 0.92 SIRT6 (0.53) SIRT6DRD2DRD3SERPINE1CA1
SCHEMBL12043237 0.92 SIRT6 (0.53) SIRT6DRD2DRD3SERPINE1MAPT
SCHEMBL12043261 0.92 SIRT6 (0.52) SIRT6DRD2SERPINE1LMNACA1
SCHEMBL12043238 0.91 SIRT6 (0.52) SIRT6DRD2DRD3SERPINE1LMNA
SCHEMBL12043242 0.91 SIRT6 (0.52) SIRT6DRD2DRD3LMNACA1
SCHEMBL12043236 0.88 SIRT6 (0.50) SIRT6DRD2DRD3SERPINE1LMNA
SCHEMBL13158554 0.87 SIRT6 (0.52) SIRT6DRD2DRD3SERPINE1LMNA
SCHEMBL12043268 0.87 SIRT6 (0.51) SIRT6DRD2DRD3SERPINE1TMEM97
SCHEMBL9984436 0.87 SIRT6 (0.51) SIRT6DRD2DRD3SERPINE1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096524-B2 Anthelmintic agents and their use INTERVET INTERNATIONAL B.V. (NL) 2015-08-04 — — US disclosed
US-9096524-B2 Anthelmintic agents and their use INTERVET INTERNATIONAL B.V. (NL) 2015-08-04 — — US disclosed
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2011-12-29 — — US disclosed
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2011-12-29 — — US disclosed
WO-2010115688-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2010-10-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE ACHE, ABCB11, MPO SIRT6 1314/4885DRD2 3527/4885DRD3 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback